{"id":"NCT01533922","sponsor":"Boehringer Ingelheim","briefTitle":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients","officialTitle":"A Randomised, Double-blind, 5 Treatment Arms, 4-period, Incomplete Cross-over Study to Determine the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (FDC) (2.5 / 5 µg; and 5 / 5 µg) (Delivered by the Respimat® Inhaler) Compared With Tiotropium (5 µg), Olodaterol (5 µg ) and Placebo (Delivered by the Respimat® Inhaler) on Lung Hyperinflation and Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease (COPD) [MORACTO TM 1]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2013-11","completion":"2013-11","firstPosted":"2012-02-16","resultsPosted":"2015-09-15","lastUpdate":"2015-09-15"},"enrollment":295,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Tiotropium","otherNames":[]},{"type":"DRUG","name":"Olodaterol","otherNames":[]},{"type":"DRUG","name":"tiotropium + olodaterol","otherNames":[]},{"type":"DRUG","name":"Tiotropium + Olodaterol","otherNames":[]},{"type":"DEVICE","name":"Respimat","otherNames":[]}],"arms":[{"label":"Tiotropium + olodaterol High dose QD","type":"EXPERIMENTAL"},{"label":"Tiotropium + olodaterol Low dose QD","type":"EXPERIMENTAL"},{"label":"Tiotropium 5 mcg QD","type":"ACTIVE_COMPARATOR"},{"label":"Olodaterol 5 mcg QD","type":"ACTIVE_COMPARATOR"},{"label":"Placebo QD","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this trial is to investigate the effect of 6 weeks treatment with tiotropium + olodaterol fixed dose combination inhalation solution on lung hyperinflation and exercise tolerance in patients with COPD","primaryOutcome":{"measure":"Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap","timeFrame":"6 weeks","effectByArm":[{"arm":"Placebo","deltaMin":2.44,"sd":0.027},{"arm":"Olodaterol 5 µg","deltaMin":2.566,"sd":0.027},{"arm":"Tiotropium 5 µg","deltaMin":2.571,"sd":0.027},{"arm":"Tiotropium + Olodaterol 2.5/5","deltaMin":2.658,"sd":0.027},{"arm":"Tiotropium + Olodaterol 5/5","deltaMin":2.685,"sd":0.027}],"pValues":[{"comp":"OG000 vs OG004","p":"<0.0001"},{"comp":"OG001 vs OG004","p":"<0.0001"},{"comp":"OG002 vs OG004","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"0.0008"},{"comp":"OG002 vs OG003","p":"0.0015"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":44,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Chile","Germany","Italy","New Zealand"]},"refs":{"pmids":["28424359"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":222},"commonTop":["Chronic obstructive pulmonary disease"]}}